| Nov 18 |
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
|
| Nov 14 |
Cabaletta Bio GAAP EPS of -$0.62 misses by $0.03
|
| Nov 14 |
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 6 |
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
|
| Oct 30 |
We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
|
| Oct 22 |
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash
|
| Oct 17 |
State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings
|
| Oct 10 |
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential
|
| Sep 25 |
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
|
| Aug 28 |
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
|
